tb management 2016
TRANSCRIPT
![Page 1: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/1.jpg)
Tuberculosis Management 2016
Department of Pharmacology
SVMC, Tirupati.
![Page 2: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/2.jpg)
• TB Burden in India• Incidence of MDR & XDR TB • Anti TB drugs• TB Management• OLD vs New regimens• Mono/Poly-drug Resistant TB Mx• MDR TB Mx• XDR TB Mx
![Page 3: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/3.jpg)
• Bedaquiline• Weight bands – What? How? Why?• Paediatric TB management• Mx of other special conditions• The End TB Strategy• References...
![Page 4: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/4.jpg)
TB Burden in India• Annually, 1/4th of Global TB Incidence.• WHO Global TB report – 2.2 million cases.
• 58% reduction in TB mortality rate; 55% reduction in TB prevalence rate by 2014 as compared to 1990 level
• The TB incidence is on declining trend.
![Page 5: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/5.jpg)
![Page 6: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/6.jpg)
![Page 7: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/7.jpg)
![Page 8: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/8.jpg)
![Page 9: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/9.jpg)
![Page 10: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/10.jpg)
![Page 11: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/11.jpg)
![Page 12: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/12.jpg)
Incidence of MDR & XDR-TB• Over 480 000 cases of multidrug-resistant (MDR) tuberculosis (TB)
occur every year globally
• 9% of them being affected by extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis.
• In India (2014), an estimated 2.2% of new cases (95% CI: 1.9–2.6%) and 15% of previously treated cases (95%CI: 11–19%) have MDR-TB.
![Page 13: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/13.jpg)
More than half of the global burden of MDR-TB is in three countries
• India• China• Russia
![Page 14: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/14.jpg)
In 2013, the average proportion of MDR-TB cases with XDR-TB was 9.0%.
![Page 15: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/15.jpg)
MDR-TB & HIV+TB Incidence
TB burden Percentage Number (millions)
MDR-TB in Notified PTB 0.071
MDR-TB in New Notified PTB 2.2% 0.024
MDR-TB in Re-Rx PTB 15% 0.047
HIV in Incident TB cases 5%
![Page 16: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/16.jpg)
Anti TB Drugs
![Page 17: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/17.jpg)
![Page 18: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/18.jpg)
New Anti TB drugs• Bedaquiline• Delamanid• Pretomanid• NC-002, NC-003• Sutezolid• SQ 109• Benzothiazinones
![Page 19: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/19.jpg)
Repurposed Anti TB drugs• Linezolid• Clofazamine• Imipenem/ Meropenem• Amoxicillin – Clavulanate• Thioacetazone• Clarithromycin
![Page 20: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/20.jpg)
TB Management
![Page 21: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/21.jpg)
CasesMicrobiologically
confirmed TB CaseClinically diagnosed
TB case
Anatomical site TB Rx History Drug resistance
Pulmonary TB
Extra Pulmonary TB
New case
Previously treated
Transferred in
MR
PDR
MDR
XDR
RR
Recurrent Rx after Failure
Rx after loss to follow up
Others
Miliary TB
![Page 22: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/22.jpg)
![Page 23: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/23.jpg)
![Page 24: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/24.jpg)
![Page 25: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/25.jpg)
![Page 26: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/26.jpg)
![Page 27: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/27.jpg)
Old vs New (2016) Regimens
![Page 28: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/28.jpg)
Rx of Drug sensitive TB:Till 2015 2016
Thrice weekly regimen Once daily for all Paediatric & PLHIV cases – 104 districts
Individual drug doses based on 3 weight bands for MDR TB Rx
FDCs based on weight bands (4 in adult, & in child) for TB Rx
Continuation of IP for 1 month if sputum positive
IP need not be continued
CP is with HR CP includes Ethambutol (HRE)For EP Tb cases, CP is for 7 mo For EP TB cases, CP is extended for
12-24 wks (3-6mo)
For TBM cases Inj SM added in IP No change in IP
![Page 29: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/29.jpg)
104 districts in 5 states• Maharashtra• Bihar• Kerala • Sikkim • Himachal Pradesh
![Page 30: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/30.jpg)
Mono/Poly-drug Resistant TB Mx• IP can be extended for maximum 3mo.
![Page 31: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/31.jpg)
RR/MDR TB MxDrugs given are -• Kanamycin• Levofloxacin• Ethionamide• Pyrazinamide• Ethambutol• Cycloserine
![Page 32: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/32.jpg)
![Page 33: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/33.jpg)
• For MDR TB cases, IP can be extended for 3mo maximum
• For all MDR TB cases with additional resistance, IP can be extended for maximum 6mo.
![Page 34: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/34.jpg)
In case of additional resistance,• Resistance to E – Omit E• Resistance to P – Omit P• Res to P&E – Add PAS in IP & CP• Res to Lfx/Mfx – use PAS + the sensitive one among them• Res to Lfx&Mfx – Clfz, Lz, PAS in IP&CP(6-12mo)• Res to any SLI – use the sensitive one• Res to all SLI - Clfz, Lz, PAS in IP&CP(6-12mo)
![Page 35: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/35.jpg)
![Page 36: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/36.jpg)
Cure: Completed treatment but consistently culture -ve (with at least 5 consecutive negative results in the last 12 to 15 months). If one follow-up +ve culture is reported during the last three quarters, patient will still be considered cured provided this positive culture is followed by at least 3 consecutive negative cultures, taken at least 30 days apart, provided that there is clinical evidence of improvement.
Treatment completed: A patient who has completed treatment according to guidelines but does not meet the definition for cure or treatment failure due to lack of bacteriological results.
Treatment failure: If >2 of 5 cultures recorded in the final 12-15 months are +ve, or if any of the final three cultures are +ve.
Treatment default: A patient whose treatment was interrupted for 2 or >2 consecutive months for any reasons.
![Page 37: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/37.jpg)
XDR TB MxDrugs given are – • Capreomycin• Moxifloxacin• Linezolid• PAS• Clofazamine• Amoxi/Clav• High Dose INH
![Page 38: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/38.jpg)
Management Guidelines for Patie nts with Documentedor Strongly Suspecte d Extensively Drug-Resista ntTuberculo sis (XDR-TB)1. Use pyrazinamide and any first-line oral agents that may be
effective.2. Use an injectable agent to which the strain is susceptible, and
consideran extended duration of use (12 months or possibly the whole
treatmentperiod). If the strain is resistant to all injectable agents, use of onethat the patient has not previously received is recommended.a3. Use a later-generation fluoroquinolone, such as moxifloxacin,
high-doselevofloxacin, or possibly gatifloxacin.b4. Use all second-line oral bacteriostatic agents (para-aminosalicylic
acid,cycloserine, and ethionamide or prothionamide) that have not beenused extensively in a previous regimen or any such agents that are
likelyto be effective.
5. Add bedaquiline or delamanid and one or more of the following drugsc:
clofazimine, linezolid, amoxicillin/clavulanic acid, clarithromycin, and carbapenems
such as imipenem/cilastatin and meropenem.6. The simultaneous use of bedaquiline and delamanid is not
recommendedat the moment in view of the current lack of information on the
potentialof adverse reactions when these drugs are administered together.7. Consider treatment with high-dose isoniazid if low-level
resistance to thisdrug is documented.8. Consider adjuvant surgery if there is localized disease.9. Enforce strong infection-control measures.10. Implement strict directly observed therapy and full adherence
support aswell as comprehensive bacteriologic and clinical monitoring.
![Page 39: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/39.jpg)
TDR TB
• No specific management guidelines mentioned by WHO/ RNTCP.
![Page 40: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/40.jpg)
Mixed resistance TB
![Page 41: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/41.jpg)
Bedaquiline (BDQ)• New class of drug - Diarylquinone.• Specifically targets Mycobacterial ATP Synthase.• Strong Bactericidal and sterilizing activity.
• June 2013 – WHO published Interim policy guidance for use of BDQ in conjunction with WHO recommended MDR-TB STRs.
• 2016 – RNTCP is introducing BDQ through conditional access programme at 6 sites in India.
![Page 42: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/42.jpg)
Criteria to receive BDQ (Apex Committee):
• Adults >18y with PTB
• Non pregnant females using non-hormonal birth control methods.
• Absence of arrhythmias or Controlled stable arrhythmias.
![Page 43: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/43.jpg)
Weight bands... What? How? Why?• Recommendation of drug doses according to weight have been
made since 2010 itself.• New (2016) guidelines by Govt of India Central TB Division provides
number of FDCs according to weight bands.• 4 weight bands for Adults, 7 for children.• This is to prevent further drug resistance and assured bioavailability
by increasing drug compliance.
![Page 44: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/44.jpg)
![Page 45: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/45.jpg)
![Page 46: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/46.jpg)
![Page 47: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/47.jpg)
Paediatric TB Mx
![Page 48: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/48.jpg)
• Children represent about 10-11% of all TB cases.
• In 2014, 81 000 children died of TB, and there were an additional 55 000 TB deaths among children who were HIV-positive.
• TB in children can be treated. Most children tolerate treatment very well.
• Preventive therapy is highly effective in children exposed to TB.
• Simple, child-friendly fixed-dose formulations are easy to administer and match WHO dosage recommendations for first line treatment.
![Page 49: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/49.jpg)
![Page 50: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/50.jpg)
• STRs to drug sensitive and MDR TB for paediatric age group are similar to adult, with dose changes.
• INH Preventive therapy for <6y age children who are – Close contacts of TB– Excluded to have active TB
• Irrespective of BCG and nutritional status.• INH 10mg/kg for 6mo given.
![Page 51: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/51.jpg)
Mx of Other Special conditions
![Page 52: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/52.jpg)
TB in Pregnancy
![Page 53: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/53.jpg)
TB in seizure pts• Prophylactic Pyridoxine (Vit B6):
– On INH – 10-25mg/d– On Cycloserine – 25mg/250mg cycloserine.
• In DR TB cases with H/O seizures, avoid– Cycloserine– Ethionamide– Fluoroquinolones
![Page 54: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/54.jpg)
TB in Psychosis pts• Psychosis Rx, Individual counselling, Group therapy, along with TB
management are essential.
• Avoid Ethionamide & FQs.
• No absolute C/I for Cycloserine, though it may cause severe psychosis and depression.Only temporary suspension advised.
• Prophylactic Pyridoxine is helpful.
![Page 55: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/55.jpg)
TB with Liver disorders
• Usual STRs for– Past h/o active hepatitis– H/o alcohol intake– Hepatitis virus carriage– No evidence of chronic liver disease
• LFTs to be done at treatment initiation for patients with unstable or advanced liver disease.
![Page 56: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/56.jpg)
If serum alanine aminotransferase is 3 times more than that at treatment initiation,
![Page 57: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/57.jpg)
DR TB in Liver disease pts:
• PZA, PAS & Ethionamide – Potentially hepatotoxic.
• Most of second line drugs are safer than first line drugs in mild hepatic impairment.
• Avoid P & E.
• If hepatic reactions occur even to second line drugs, consider & evaluate other causes.
![Page 58: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/58.jpg)
End TB Strategy
![Page 59: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/59.jpg)
• WHO’s End TB Strategy
The strategy aims to end the global TB epidemic, with targets to reduce TB deaths by 95% and to cut new cases by 90%
between 2015 and 2035, and to ensure that no family 100% is burdened with catastrophic expenses due to TB.
![Page 60: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/60.jpg)
References
• http://tbcindia.nic.in Central Tuberculosis Division, Govt Of India.• WHO website http://www.who.int/tb/en/• Goodman & Gilman, The Pharmacological basis of Therapeutics
12th Ed.• K.D. Tripathi, Essentials of Medical Pharmacology, 7th Ed.• Harrison’s Principles of Internal Medicine 19th Ed.
![Page 61: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/61.jpg)
![Page 62: Tb management 2016](https://reader035.vdocument.in/reader035/viewer/2022062904/587727851a28ab2b2c8b4ff1/html5/thumbnails/62.jpg)